New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect
Silvio Inzucchi summarises recent developments in treatment of type 2 diabetes. Some new agents yield clear CV event risk reduction, while older glucose-lowering medication only had a moderate effect on CV events.
Vascular Biology Working Group Meeting at ACC 2016, Chicago, IL, USA
Silvio E. Inzucchi, MD - Professor of Medicine, Yale University School of Medicine, New Haven, CT, USA